Atherosclerosis: ApoB, Lp(a), and the Particles Behind Plaque

REVIEWED BY

William Maish, MD MBA MPH

Clinical Product Lead

Published

Last updated

Key takeaway:

Atherosclerosis testing uses six blood markers—LDL, ApoB, Lp(a), hs-CRP, AIP, and AC—to quantify atherogenic particle burden, inherited plaque risk, and vessel-wall inflammation years before symptoms appear. ApoB reflects particle number that drives plaque entry; Lp(a) adds inherited thrombotic risk (desirable <30, high-risk ≥50). Monitoring this panel is associated with connecting lipid transport, vascular inflammation, and coagulation into a unified picture of arterial aging.

Read more →

Understand what your heart cardiovascular testing results really mean

See your biomarkers in context with a comprehensive panel.

  • CLIA-certified labs
  • HIPAA compliant
  • Personalized health protocol
Book your test

Atherosclerosis and the particle, inflammation, and inheritance signals

Atherosclerosis biomarkers are blood signals that reveal how actively plaque is forming and how risky it may be, often years before symptoms. They illuminate three core processes. First, the traffic of cholesterol‑laden particles that enter artery walls (apoB‑containing lipoproteins such as LDL and remnant particles), including a particularly sticky, inherited form (lipoprotein(a), Lp(a)). Second, the vessel wall’s inflammatory state, which drives plaque growth and fragility (high‑sensitivity C‑reactive protein, hs‑CRP, and other inflammatory mediators). Third, the readiness of blood to clot if a plaque ruptures (prothrombotic factors like fibrinogen and platelet activation markers). Together, these markers offer a dynamic picture of arterial injury, repair, and risk—not just a snapshot of cholesterol. Testing helps identify people whose plaques are likely to progress or rupture, guides the intensity and type of treatment, and tracks whether therapies are calming inflammation and reducing atherogenic particle burden. In short, atherosclerosis biomarkers translate invisible artery biology into actionable information.

Join 150,000+ others building better health

Get the science behind better health, every week.

By clicking “Subscribe” you agree to our Terms of Service and Privacy Policy.

Why particle count beats cholesterol alone

Atherosclerosis biomarkers are blood signals that reveal how aggressively cholesterol-carrying particles and inflammation interact with your artery walls. They map the pressure on the endothelium, the tendency to form plaque, and the stability of that plaque—processes that shape oxygen delivery to the heart, brain, kidneys, and limbs long before symptoms appear. LDL and ApoB quantify the atherogenic “traffic” in your bloodstream; ApoB reflects particle number, which drives plaque entry. Lp(a) adds inherited “stickiness” and thrombosis risk. hs-CRP captures vessel-wall inflammation. Composite ratios like AIP and AC integrate triglycerides, HDL, and total cholesterol to estimate particle atherogenicity. Reference intervals vary by lab, but cardiovascular risk generally falls as LDL, ApoB, Lp(a), hs-CRP, AIP, and AC move toward the lower end; higher values point to more particle burden, inflammation, and plaque growth. Many people feel fine until angina, transient neurologic symptoms, erectile dysfunction, or exertional calf pain signal advanced disease. When these markers are low, physiology tilts toward endothelial healing: fewer apoB-containing particles cross into the wall, less oxidized lipid accumulates, and inflammation quiets. Low Lp(a) indicates minimal inherited contribution. Very low lipid values can occur with hyperthyroidism, malabsorption, or serious illness. Children typically sit lower; pregnancy raises LDL, ApoB, and Lp(a); premenopausal women often have lower ApoB/LDL than men, with values rising after menopause. Big picture: this panel links lipid transport, inflammation, coagulation, and vascular biology. Tracked over time and interpreted with blood pressure, glucose and insulin status, kidney and thyroid function, it refines lifetime risk for heart attack, stroke, and peripheral vascular disease by showing how your arteries are coping right now.

Test 100+ biomarkers from home

One blood draw. A full picture of your health, explained in plain language.

Book your test

What a blood panel reveals about artery health

Atherosclerosis blood testing provides a window into the health of your arteries and the systems they support, including your heart, brain, and metabolic function. When arteries become narrowed or stiffened by plaque, it can disrupt blood flow and impact everything from energy delivery to cognitive performance and immune resilience. At Superpower, we assess your risk and vascular health by measuring LDL cholesterol, ApoB, lipoprotein(a) [Lp(a)], high-sensitivity C-reactive protein (hs-CRP), the atherogenic index of plasma (AIP), and the atherogenic coefficient (AC).LDL cholesterol, often called “bad cholesterol,” is a key carrier of cholesterol in the blood and a major contributor to plaque buildup. ApoB is a protein found on all atherogenic lipoproteins, providing a direct count of particles that can enter artery walls. Lp(a) is a genetic variant of LDL that is particularly prone to promoting plaque and clot formation. hs-CRP is a marker of low-grade inflammation, signaling immune activity that can destabilize plaques. AIP and AC are calculated ratios that reflect the balance between protective and harmful lipids, offering a broader view of your lipid-related risk. Healthy levels of these markers suggest stable arteries and efficient blood flow, supporting optimal function across body systems. Elevated or imbalanced results may indicate increased risk for atherosclerosis, even before symptoms appear, highlighting the importance of early detection. Interpretation of these biomarkers can be influenced by factors such as age, sex, pregnancy, acute illness, certain medications, and laboratory methods. These variables should be considered when evaluating your results.

Frequently Asked Questions

References

  1. Libby P, Buring JE, Badimon L, Hansson GK, Deanfield J, Bittencourt MS, Tokgözoğlu L, Lewis EF (2019). Atherosclerosis. *Nature Reviews. Disease Primers*, *5*(1), 56. https://doi.org/10.1038/s41572-019-0106-z
  2. Sniderman AD, Thanassoulis G, Glavinovic T, Navar AM, Pencina M, Catapano A, Ference BA (2019). Apolipoprotein B particles and cardiovascular disease: A narrative review. *JAMA Cardiology*, *4*(12), 1287-1295. https://doi.org/10.1001/jamacardio.2019.3780
  3. Kronenberg F, Mora S, Stroes ESG, Ference BA, Arsenault BJ, Berglund L, Dweck MR, Koschinsky M, Lambert G, Mach F, McNeal CJ, Moriarty PM, Natarajan P, Nordestgaard BG, Parhofer KG, Virani SS, von Eckardstein A, Watts GF, Stock JK, ... Catapano AL (2022). Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis: A European Atherosclerosis Society consensus statement. *European Heart Journal*, *43*(39), 3925-3946. https://doi.org/10.1093/eurheartj/ehac361
  4. Ridker PM, Everett BM, Thuren T, MacFadyen JG, Chang WH, Ballantyne C, Fonseca F, Nicolau J, Koenig W, Anker SD, Kastelein JJP, Cornel JH, Pais P, Pella D, Genest J, Cifkova R, Lorenzatti A, Forster T, Kobalava Z, ... Glynn RJ (2017). Antiinflammatory therapy with canakinumab for atherosclerotic disease. *The New England Journal of Medicine*, *377*(12), 1119-1131. https://doi.org/10.1056/NEJMoa1707914
  5. Emerging Risk Factors Collaboration, Kaptoge S, Di Angelantonio E, Lowe G, Pepys MB, Thompson SG, Collins R, Danesh J (2010). C-reactive protein concentration and risk of coronary heart disease, stroke, and mortality: An individual participant meta-analysis. *Lancet*, *375*(9709), 132-140. https://doi.org/10.1016/S0140-6736(09)61717-7

Led by doctors with 40 years of health and longevity expertise

Dr. Anant Vinjamoori

Dr. Anant Vinjamoori, MD

Chief Longevity Officer, Superpower

Dr. Leigh Erin Connealy

Dr. Leigh Erin Connealy, MD

Clinician & Founder of The Centre for New Medicine

Dr. Robert Lufkin

Dr. Robert Lufkin, MD

Physician & UCLA Medical School Professor, NYT bestselling author

Dr. Abe Malkin

Dr. Abe Malkin, MD

Founder & Medical Director of Concierge MD

Membership 1
1 / 4

Your membership starts here

Annual 100+ biomarker panel

  • Data dashboard and digital twin
  • Upload past labs and connect wearables
  • Personalized health protocol
  • 24/7 care team access
  • AI companion for all health questions
  • Marketplace with additional solutions
$199
/year*Billed annually
Get started
HSA/FSA eligibleCancel anytimeResults in a week

*Pricing may vary for members in New York and New Jersey